Who is sponsoring NCT05705336?

NCT05705336 is sponsored by Alejandro Reyes Sánchez.

What drugs are being tested in NCT05705336?

Interventions in NCT05705336: Tranexamic Acid Oral Product, Placebo pills.

What condition does NCT05705336 study?

NCT05705336 studies Tranexamic Acid (TXA), Prospective Study, Evidence-based Medicine, Randomized Controlled Trial.

Is NCT05705336 still recruiting?

NCT05705336 is currently completed. Last updated 30 January 2023.

Last reviewed 2023-01-30 · How we verify

NCT05705336

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial Analyzing the Efficacy of Oral Administration of Tranexamic Acid in Spine Surgery.

Completed Phase 4 Last updated 30 January 2023

What this trial tests

Phase 4 trial testing Tranexamic Acid Oral Product in Tranexamic Acid (TXA) in 60 participants. Completed in 1 January 2022.

Timeline

1 January 2021

Primary endpoint
30 December 2021

1 January 2022

Quick facts

Lead sponsor	Alejandro Reyes Sánchez
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	60
Start date	1 January 2021
Primary completion	30 December 2021
Estimated completion	1 January 2022
Sites	1 location across Mexico

Drugs / interventions tested

Tranexamic Acid Oral Product — full drug profile →
Placebo pills — full drug profile →

Conditions studied

Tranexamic Acid (TXA) — all drugs for Tranexamic Acid (TXA) →
Prospective Study — all drugs for Prospective Study →
Evidence-based Medicine — all drugs for Evidence-based Medicine →
Randomized Controlled Trial — all drugs for Randomized Controlled Trial →

Sponsor

Alejandro Reyes Sánchez — full company profile →

Who can join

Adults 40 to 70, any sex, with Tranexamic Acid (TXA) or Prospective Study. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study design: Randomized control trial Purpose: Evaluate the efficacy of oral administration of tranexamic acid (TXA) in spine surgeries to achieve blood loss reduction. Methods. A total of 60 patients undergoing major surgery of the spine, were randomly assigned into 2 groups. Group 1 was assigned as the control group and the other one included oral administration of tranexamic acid 2 hours prior to surgery. Outcomes measures included intraoperative blood loss, postoperative blood loss, hematological parameters, blood transfusion needed, and surgical complications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Tranexamic Acid Oral Product

Trials testing the same drug.

NCT04691362 — Noninferiority Oral Tranexamic Acid vs Intravenous Administration in Total Hip Arthroplasty · Phase 4 · completed
NCT03751163 — Oral Tranexamic Acid and Topical Hydroquinone in the Treatment of Melasma · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05705336 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alejandro Reyes Sánchez
Last refreshed: 30 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05705336.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing